Clinical Trials Browser

Phase 3 × Carcinoma × lanreotide × Clear all

NCT00216372 2020-11-05

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Phase 3 Completed

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms